Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 7.8% - Here's What Happened

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) were up 7.8% during trading on Monday . The company traded as high as $27.30 and last traded at $27.09. Approximately 142,627 shares were traded during trading, a decline of 51% from the average daily volume of 290,740 shares. The stock had previously closed at $25.12.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. Oppenheimer boosted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, November 11th. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a "buy" rating for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $46.43.

Dianthus Therapeutics Stock Performance

The stock's 50 day moving average is $24.70 and its 200 day moving average is $26.60. The company has a market capitalization of $800.30 million, a PE ratio of -10.82 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its stake in Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock valued at $2,095,000 after acquiring an additional 72,509 shares in the last quarter. Rhumbline Advisers bought a new position in Dianthus Therapeutics in the 2nd quarter valued at $832,000. American Century Companies Inc. grew its position in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock valued at $788,000 after purchasing an additional 8,473 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Dianthus Therapeutics in the second quarter worth $265,000. Finally, Great Point Partners LLC raised its position in shares of Dianthus Therapeutics by 21.3% in the second quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock worth $19,615,000 after buying an additional 132,929 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.